ReviewAdvances in experimental medicine and biology2026
Effectiveness of Cognitive Enhancement Programs in Parkinson's Disease Patients with Mild Cognitive Impairment: A Narrative Review.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectParkinson's disease (PD) is a chronic progressive neurodegenerative disease. Although PD has been associated mainly with the onset of motor symptoms, cognitive impairment is an equally important feature of the disease. The high prevalence of cognitive impairment in PD makes the implementation of cognitive enhancement programs particularly important.
aimThis narrative review evaluates the effectiveness of cognitive enhancement programs in Parkinson's disease patients with mild cognitive impairment (PD-MCI) according to the results of English language studies that have been published in PubMed and Google Scholar electronic databases until May 2024 (no initiation date).
resultsSixteen studies encompassing 828 participants were included. Cognitive enhancement programs appear to have a positive effect on various cognitive domains, such as overall cognition, memory, executive functions, attention, information processing speed, and visuospatial functions. However, the results regarding the improvement of patients' mood and quality of life are not very encouraging, as the majority of studies did not observe significant improvements after the intervention, which raises questions about the appropriateness of these programs in these aspects.
conclusionsCognitive enhancement programs appear to offer significant benefits for delaying cognitive decline in patients with PD-MCI. However, further research is needed to optimize interventions and understand their underlying action mechanisms by conducting future research studies focusing on the implementation of combined and individualized interventions.
Indexed as
Identifiers
41273543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.